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Over the past years methods have been developed to generate 3-
dimensional, spontaneously and coherently beating engineered heart
tissues (EHT) from embryonic chick, neonatal rat and mouse cardiac
myocytes. Circular EHT may be useful as an in vitro model for
target validation and drug screening for several reasons. (i) The
system provides cardiac cells with a more physiological, 3D envi-
ronment than classical 2D cultures, (ii) allows measurement of force
of contraction, contraction kinetics and beating rate under con-
trolled, isometric conditions, (iii) is stable for weeks, and (iv) allows
efﬁcient genetic manipulation with adeno- and lentivirus (overex-
pression, gene silencing). On the other hand, EHT have been tested
as graft material for cardiac repair and improved the function of
infarcted rat hearts. To translate the EHT approach to patients and to
develop a human heart muscle system, recent efforts concentrate on
optimizing experimental conditions for generating EHTs from hu-
man embryonic (hESC) and adult stem cells. To this end, cells from
hESC-derivedspontaneouslybeatingembryoidbodiescanbedispersed
and reassembled to generate human EHTs that contract synchro-
nously, develop force of contraction and react to pharmacological
stimulation qualitatively similar to normal human heart muscle.
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Hydrogels are potential candidates for Tissue engineering (TE),
because of their water content, transport properties, and tissue like
physical and chemical behaviour. This project was based on the
production and characterization of implantable stimuli responsive
scaffolds made of hyaluronic acid (HA) that presents a high water
retention character, in combination with 2-ethyl (2-pyrrolidone)
methacrylate (EPM), possessing temperature-dependent solubility
in water, by bulk polymerization.
Semi-interpenetrated networks were produced with different
EPM and HA concentrations using K2S2O8 as an initiator and
triethylene glycol dimethacrylate or N,N-methylene-bisacrylamide
as crosslinkers. PEPM-HA hydrogels were washed and freeze
dried. Characterization of the systems was assessed by NMR,
ATR-FTIR and SEM techniques. The swelling degree and degra-
dation behaviour studies were conducted in a phosphate buffer
solution. Biocompatibility studies were performed by culturing
bovine chondrocytes (BC), L929, ROS and MES in the PEPM-HA
hydrogels. After evaluating the cells’ viability, BC were cultured
under agitation for a period of 6 weeks. Distribution, morphology
and extracellular matrix components deposition during the exper-
iment were analysed. The different combinations of EPM-HA and
crosslinkers led to hydrogels with different porous structures that
could be intimately related to their swelling character. When BC
where incubated for 72 h in different PEPM-HA hydrogels, cells
remained viable and therefore were cultured for a longer period of
time to predict their suitability for a cartilage TE approach. PEPM-
HA hydrogels may constitute a valid alternative for pursuing future
cartilage tissue engineering strategies.
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Introduction: Using a hypertrophic cartilage graft could be an al-
ternative approach to bone repair. Cartilage can survive in a rela-
tively hypoxic environment, giving time for vascularization of the
engineered graft to develop post-implantation. The aim of this
research was to utilize different culture conditions to investigate
whether nasal chondrocytes may be used to generate a cartilage
construct with characteristics of hypertrophic tissue.
Methods: Rat nasal chondrocytes (P2) were cultured as pellets
and on PGA scaffolds under conditions that could promote hy-
pertrophic differentiation and matrix mineralisation (chondro-
genic and osteogenic medium, addition of BMP-2, -7, leptin,
b-glycerophosphate). Chondrocyte differentiation was evaluated by
immunolocalisation of collagens (types I, II and X) and histo-
chemical detection of proteoglycans, calcium deposition and alka-
line phosphatase. Further investigation of phenotype (e.g. MMP13,
VEGF, annexin, Runx2 gene expression) and potential of human
nasal chondrocytes in hypetrophic cartilage formation is ongoing.
Results and Conclusion: Expanded chondrocytes successfully re-
differentiated in pellets and on PGA scaffolds. Alkaline phosphatase
activity and collagen type X expression was detected mainly in PGA
constructs, and suggested that chondrocytes were entering the hy-
pertrophic stage (however no matrix mineralisation was detected
even with b-glycerophosphate). In conclusion, nasal chondrocytes
may express a hypertrophic-like phenotype and therefore show some
potential in bone tissue engineering strategies.
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